fashion -WSS

fashion

author：explore 2025-09-30 23:33:14 - browse：7

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Biogen joins immunology wave with $1.15 billion acquisition of HI

WSS

Childhood cancer progress stalls for Black, Hispanic kids: Report

Making the case for fair compensation in clinical trials

Addressing health care workers' trauma can help fight burnout

ASCO eve: Let’s set the table for this year's meeting

Liver decline slowed by off

Digital health: a case of mistaken identity

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

Anthos stroke drug appears safer than common blood thinner

Activists slam private health insurers over coverage restrictions

Morphosys mixed study results for blood cancer drug

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

The high cost of giving birth even with insurance

Questions and answers about ramping up H5N1 bird flu vaccine

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

hotspot

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Ransomware attacks on hospitals: Study outlines patient impact

Does good food count as health care? Study aims to find out

Study finds gene variants tied to breast cancer risk in Black women

Gain of function research would be limited under House proposal

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

explore

hotspot

focus

Wikipedia